Key result
Intravenous beta-blockade and extracorporeal life support successfully treated refractory pulseless polymorphic ventricular tachycardia in a 12-year-old boy, yielding excellent neurological outcome.
Case Report (n=1)
Intravenous beta-blockade combined with extracorporeal life support can be a successful rescue strategy for refractory pulseless polymorphic ventricular tachycardia in pediatric CPVT.
May support beta-blockade plus ECLS rescue in refractory pediatric CPVT; hypothesis-generating and requires prospective validation.
We describe a case of refractory pulseless polymorphic ventricular tachycardia successfully treated with a bolus of propranolol intravenously, followed by an esmolol infusion and extracorporeal life support for 4 days in a 12-year-old boy later diagnosed with catecholaminergic polymorphic ventricular tachycardia. He had an excellent neurological outcome. Genetic testing for mutations associated with cardiac arrhythmias yielded a mutation of the syntrophin α-1 gene. The pathogenicity of this specific variant is uncertain. A mutation of this gene at a different locus is implicated in rare cases of long-QT syndrome. The patient subsequently underwent left cardiac sympathetic denervation followed by implantable cardiac defibrillator insertion. He remains symptom and arrhythmia free on atenolol.
No takes yet. Share an insight, caveat, or question.
Cafferkey et al. (2018) conducted a case report in Refractory pulseless polymorphic ventricular tachycardia / Catecholaminergic polymorphic ventricular tachycardia (n=1). Intravenous propranolol, esmolol infusion, and extracorporeal life support was evaluated on Clinical and neurological outcome. Intravenous beta-blockade and extracorporeal life support successfully treated refractory pulseless polymorphic ventricular tachycardia in a 12-year-old boy, yielding excellent neurological outcome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: